An observational study in Acute Hypoxemic Respiratory Failure and COVID 19, sponsored by Hospital del Mar Research Institute (IMIM). Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.
Sponsored by Hospital del Mar Research Institute (IMIM) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 26th largest by enrollment of the 31 observational ones that give a count, is one of 11 that started in 2020, is one of 31 observational ones, and was the 55th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Hospital del Mar Research Institute (IMIM) · Sites in Spain
Ages 18+
Medipol University · Sites in Spain, Chile, Egypt and 3 more countries
Ages 18–89
Centro de Emergencias Sanitarias 061 Andalucía · Sites in Spain
BioAegis Therapeutics Inc. · Sites in Spain, United States, Belgium and 10 more countries
Ages 18+
University Health Network, Toronto · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 100 across 456 observational studies indexed under Respiratory Insufficiency.
Median enrollment 116 across the 38 interventional studies, 298 across the 31 observational. Of the 42 that completed or were terminated, 6 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 69 have an industry lead sponsor. The 10 most frequent:
Hospital del Mar Research Institute (IMIM) is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Hospital del Mar Research Institute (IMIM) has 3 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT07178483Hospital Universitari de BellvitgeEvaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure | 2027-03-01 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
| NCT07708506Jesus VillarIs Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study) | 2027-07-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this prospective observational cohort study is to develop a predictive model for high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF) caused by SARS-CoV-2. By combining clinical data and metabolomic profiles, the study seeks to answer:
Participants with AHRF due to SARS-CoV-2 receiving HFNC under standard-of-care protocols will be monitored until hospital discharge or death. Blood samples for metabolomic analysis will be collected at inclusion.
This prospective observational cohort study focuses on developing and validating a predictive model for HFNC failure in patients with SARS-CoV-2-related AHRF, combining clinical parameters and metabolomic profiling. Patients received standard-of-care therapy based on hospital protocols, with clinical data and plasma samples collected at inclusion (T0) for laboratory and metabolomic analyses.
The study consists of two cohorts: a Training Cohort (March 2020 to April 2021) for model development and a Validation Cohort (May 2021 to October 2021) for model validation and external testing. HFNC outcomes were classified as success or failure, with failure defined as requiring orotracheal intubation (OTI). Advanced machine-learning techniques were employed for feature selection and model optimization, targeting precise integration of clinical and metabolomic data.
This model seeks to enhance early identification of HFNC failure risk, enabling timely interventions and personalized management in critically ill AHRF patients.
Patients admitted to Hospital del Mar in Barcelona, Spain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants included from March 2020 to April 2021 for model development.
Participants included from May 2021 to October 2021 for model validation.
Predictive Model Development
Area Under the Receiver Operating Characteristic Curve (AUC) of the final predictive model for identifying HFNC failure, measured at the time of study inclusion (T0).
Time frame: From the initiation of HFNC until the need for intubation, hospital discharge, or death, whichever occurs first (up to 28 days). Completed using the Training Cohort (March 2020 to April 2021).
Identification of Key Metabolites
Concentrations of key metabolomic markers (e.g., anthranilic acid, octanoic acid) associated with HFNC failure, measured at T0.
Time frame: At study inclusion (T0).
Validation of the Predictive Model
Performance of the predictive model in the Validation Cohort. Area Under the Receiver Operating Characteristic Curve (AUC) of the final predictive model for identifying HFNC failure, measured at the time of study inclusion (T0).
Time frame: From the initiation of HFNC until the need for intubation, hospital discharge, or death, whichever occurs first (up to 28 days). Completed during the Validation Cohort phase (May to October 2021).
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2020 to primary completion in Sep 2021, 18 months.
Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 18 months is below that.
Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital del Mar Research Institute (IMIM)